EP3790465A1 - Sensing systems and methods for identifying emotional stress events - Google Patents
Sensing systems and methods for identifying emotional stress eventsInfo
- Publication number
- EP3790465A1 EP3790465A1 EP19716019.5A EP19716019A EP3790465A1 EP 3790465 A1 EP3790465 A1 EP 3790465A1 EP 19716019 A EP19716019 A EP 19716019A EP 3790465 A1 EP3790465 A1 EP 3790465A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- lactate
- processor
- change
- lactate concentration
- emotional stress
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002996 emotional effect Effects 0.000 title claims abstract description 108
- 238000000034 method Methods 0.000 title claims description 56
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims abstract description 313
- 230000008859 change Effects 0.000 claims abstract description 117
- 238000001727 in vivo Methods 0.000 claims abstract description 25
- 102000004190 Enzymes Human genes 0.000 claims description 29
- 108090000790 Enzymes Proteins 0.000 claims description 29
- 229920000642 polymer Polymers 0.000 claims description 13
- 230000004044 response Effects 0.000 claims description 12
- 238000003780 insertion Methods 0.000 claims description 9
- 230000037431 insertion Effects 0.000 claims description 9
- 239000013060 biological fluid Substances 0.000 claims description 8
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims description 7
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims description 7
- 108010073450 Lactate 2-monooxygenase Proteins 0.000 claims description 7
- 230000001133 acceleration Effects 0.000 claims description 6
- 102000016938 Catalase Human genes 0.000 claims description 4
- 108010053835 Catalase Proteins 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 230000004962 physiological condition Effects 0.000 abstract description 2
- 230000036578 sleeping time Effects 0.000 abstract 1
- 238000003066 decision tree Methods 0.000 description 14
- 239000010410 layer Substances 0.000 description 13
- 239000012491 analyte Substances 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 238000004891 communication Methods 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 238000012544 monitoring process Methods 0.000 description 9
- 230000036541 health Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 230000027756 respiratory electron transport chain Effects 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000002500 effect on skin Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000001788 irregular Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000010586 diagram Methods 0.000 description 6
- 238000011545 laboratory measurement Methods 0.000 description 6
- 230000004622 sleep time Effects 0.000 description 6
- 230000036642 wellbeing Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000003989 dielectric material Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 230000002618 waking effect Effects 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010029412 Nightmare Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002730 additional effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000012806 monitoring device Methods 0.000 description 2
- -1 polyvinylferrocene) Chemical compound 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- AOBIOSPNXBMOAT-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethoxy)ethoxymethyl]oxirane Chemical compound C1OC1COCCOCC1CO1 AOBIOSPNXBMOAT-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- BXNJHAXVSOCGBA-UHFFFAOYSA-N Harmine Chemical compound N1=CC=C2C3=CC=C(OC)C=C3NC2=C1C BXNJHAXVSOCGBA-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229940075397 calomel Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 238000003869 coulometry Methods 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- ZOMNIUBKTOKEHS-UHFFFAOYSA-L dimercury dichloride Chemical compound Cl[Hg][Hg]Cl ZOMNIUBKTOKEHS-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 239000012992 electron transfer agent Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000003893 lactate salts Chemical group 0.000 description 1
- 239000012633 leachable Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000075 poly(4-vinylpyridine) Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002717 polyvinylpyridine Polymers 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14503—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
Definitions
- Lactate is one analyte whose in vivo levels may vary in response to numerous environmental or physiological factors including, for example, eating, stress, exercise, sepsis or septic shock, hypoxia, presence of cancerous tissue, and the like.
- periodic laboratory measurements of lactate levels may be sufficient to determine whether these conditions are increasing or decreasing in severity.
- Periodic laboratory measurements of lactate levels may be wholly inadequate for monitoring short-lived, acute events, however. Namely, the measurement frequency may not be regular enough to observe a lactate spike (increase) above baseline in an individual experiencing a lactate-changing stimulus.
- FIG. 1 shows a diagram of an illustrative sensing system that may incorporate a lactate-responsive sensor of the present disclosure.
- FIG. 2A shows a diagram of an illustrative two-electrode sensor configuration compatible for use in the disclosure herein.
- FIG. 2B shows a diagram of an illustrative three-electrode sensor configuration compatible for use in the disclosure herein.
- FIG. 2C shows a diagram of another configuration of an illustrative three-electrode sensor configuration compatible for use in the disclosure herein.
- FIG. 3 shows an illustrative decision tree that may be executed by a processor within the sensing systems of the present disclosure, in which elevated lactate levels occurring during sleep or exercise may be determined as being unrelated to an emotional stress event.
- FIG. 4 shows an illustrative decision tree that may be executed by a processor within the sensing systems of the present disclosure, in which elevated lactate levels occurring during sleep or exercise or as a result of eating may be determined as being unrelated to an emotional stress event.
- FIG. 5 shows a plot of in vivo measured lactate concentrations as a function of time.
- the present disclosure generally describes methods for monitoring and managing emotional stress and, more specifically, systems and methods for monitoring lactate in vivo for management of emotional stress.
- lactate concentrations in an individual may be diagnostic of exposure to various physiological and environmental factors.
- Laboratory measurements of lactate concentrations may be sufficient to monitor chronic lactate-altering conditions, but such an approach may be wholly inadequate when acute factors or conditions alter lactate concentrations in vivo, especially when lactate concentrations fluctuate rapidly in response to a particular stimulus. More specifically, laboratory measurements of lactate concentrations may not occur with sufficient frequency or analysis rapidity to observe a lactate spike, and even if observed, it may not be possible to take proactive action in response to an irregular (elevated) lactate concentration. While some factors leading to elevated lactate concentrations are benign, other factors may lead to problematic health consequences if not addressed in a suitable manner.
- analyte sensors that are responsive to lactate in vivo may be operable to provide a plurality of lactate concentrations with sufficient frequency and analytical rapidity to observe lactate spikes during or shortly after their occurrence (/.e., in real-time or near real-time).
- the analyte sensors described herein may facilitate a proactive response to lactate-altering physiological and/or environmental factors, should the factor be identified as substantially non-benign in nature and worthy of proactive management. Proactive management of emotional stress represents one instance where monitoring lactate concentrations in vivo may allow substantial health and well-being benefits to be realized.
- the present disclosure further describes sensing systems incorporating a lactate-responsive sensor, in which various sensing components, such as a processor and/or instructions coded therein, are adapted to identify various lactate-altering factors that may benignly cause a lactate spike or similar lactate concentration deviation.
- Example factors leading to a benign (harmless) lactate spike may include, for instance, exercise or eating.
- the sensing systems described herein may be adapted to discriminate between lactate spikes arising from exposure to benign or non-benign lactate-altering factors.
- the sensing systems described herein may allow a user to proactively address elevated and/or rapidly changing lactate concentrations that are potentially related to various health and well-being issues.
- the sensing systems may further query a user (/.e., a primary user or wearer of a lactate-responsive sensor), a designated individual, or a group concerning the individual's health and/or emotional status in light of an observed lactate spike, which may further facilitate proactive health and well-being management, according to certain embodiments.
- the sensing systems may query a user about their lifestyle during a given period of time, and the sensing systems may retrospectively analyze the sensor data to determine if a correlation exists between particular lifestyle events (e.g., those producing emotional stress) and an observed lactate spike or similar lactate concentration irregularity.
- the sensing systems described herein may advantageously help a user better manage emotional stress by maintaining lactate concentrations within a desired range. While emotional stress is an unavoidable consequence of daily life, the sensing systems described herein may help decrease the intensity of an emotional stress event by informing a user or other individual when lactate concentrations are indicative that a severe emotional stress event is occurring, has occurred, or is about to occur. Improved health and well- being outcomes therefore may result from proactive management of the emotional stress event.
- sensing systems of the present disclosure may comprise: a lactate-responsive sensor adapted for detecting lactate in vivo ; and a processor communicatively coupled to the lactate- responsive sensor.
- the processor is adapted to determine a plurality of lactate concentrations measured by the lactate-responsive sensor over a period of time.
- the processor is further adapted to correlate a lactate spike, a lactate concentration change, and/or a lactate concentration rate of change to an emotional stress event occurring within the period of time.
- Emotional stress events that may be identified by the sensing systems and methods of the present disclosure include, but are not limited to, arguments, fights, relationship issues, emotional or physical trauma, terror, fear, paranoia, anxiety, and the like. Identification may occur through correlation to a lactate spike, lactate concentration change, and/or lactate concentration rate of change. Benign lactate-altering factors that may be identified as such by the sensing systems include, for example, exercise and eating. Thus, a lactate spike, lactate concentration change, and/or lactate concentration rate of change occurring in conjunction with a benign lactate-altering factor is not generally correlated with a genuine emotional stress event, such as those noted above. Additional lactate-altering factors that can be definitively determined as not arising from emotional stress (e.g., during sleep) may be identified by the sensing systems as well.
- lactate-responsive sensors suitable for incorporation within the sensing systems and methods of the present disclosure are provided hereinafter. It is to be appreciated, however, that lactate-responsive sensors having architectures, configurations, and/or components different than or in addition to those described expressly hereinafter may also be used suitably in some embodiments of the present disclosure. In general, any lactate-responsive sensor that is suitable for in vivo disposition may be used in the various embodiments of the present disclosure.
- a housing for the lactate-responsive sensor may be adapted to be worn on-body, and at least a portion of the lactate- responsive sensor may protrude from the housing for insertion in vivo.
- An active sensing region may be located upon at least a portion of the portion of the lactate-responsive sensor protruding from the housing, particularly a portion of the sensor configured for insertion in vivo.
- the active sensing region may comprise a sensing layer comprising a polymer and a lactate- responsive enzyme, according to various embodiments.
- lactate-responsive sensors of the present disclosure may be situated in any suitable location in vivo. Suitable locations may include, but are not limited to, intravenous, subcutaneous, or dermal locations. Intravenous sensors have the advantage of analyzing lactate directly in blood, but they are invasive and can sometimes be painful for an individual to wear over an extended period. Subcutaneous and dermal analyte sensors can often be less painful for an individual to wear and can provide sufficient measurement accuracy in many cases. In more particular embodiments, certain lactate- responsive sensors suitable for use in the present disclosure may be dermal sensors configured to assay dermal fluid of a user.
- FIG. 1 shows a diagram of an illustrative sensing system that may incorporate a lactate-responsive sensor of the present disclosure.
- sensing system 100 includes sensor control device 102 and reader device 120 that are configured to communicate with one another over a local communication path or link, which may be wired or wireless, uni- or bi-directional, and encrypted or non-encrypted.
- Reader device 120 may constitute an output medium for viewing lactate concentrations and alerts or notifications determined by sensor 104 or a processor associated therewith, as well as allowing for one or more user inputs, according to some embodiments.
- Reader device 120 may also be in communication with remote terminal 170 and/or trusted computer system 180 via communication path(s)/link(s) 141 and/or 142, respectively, which also may be wired or wireless, uni- or bi-directional, and encrypted or non-encrypted.
- Any suitable electronic communication protocol may be used for each of the communication paths or links, such as near field communication (NFC), radio frequency identification (RFID), BLUETOOTFI® or BLUETOOTFI® Low Energy protocols, WiFi, or the like.
- Remote terminal 170 and/or trusted computer system 180 may be accessible, according to some embodiments, by individuals other than a primary user who have an interest in the user's lactate levels or emotional stress events (e.g., parents, siblings, physicians, therapists, teachers, and the like).
- Reader device 120 may comprise display 122 and optional input component 121.
- Display 122 may comprise a touch-screen interface, according to some embodiments.
- Sensor control device 102 includes sensor housing 103, which may house circuitry and a power source for operating sensor 104.
- a processor (not shown) may be communicatively coupled to sensor 104, with the processor being physically located within sensor housing 103 or reader device 120.
- Sensor 104 protrudes from the underside of sensor housing 103 and extends through adhesive layer 105, which is adapted for adhering sensor housing 103 to a tissue surface, such as skin, according to some embodiments.
- Sensor 104 is adapted to be at least partially inserted into a tissue of interest, such as within the dermal layer of the skin.
- Sensor 104 may comprise a sensor tail of sufficient length for insertion to a desired depth in a given tissue.
- the sensor tail may comprise a sensing region or sensing layer that is active for sensing lactate, and may comprise a lactate-responsive enzyme, according to one or more embodiments.
- the sensing region or sensing layer may include a polymeric material to which the lactate-responsive enzyme is covalently bonded, according to some embodiments.
- lactate may be monitored in any biological fluid of interest such as dermal fluid, plasma, blood, lymph, synovial fluid, cerebrospinal fluid, saliva, bronchoalveolar lavage, amniotic fluid, or the like.
- lactate-responsive sensors of the present disclosure may be adapted for assaying dermal fluid.
- an introducer may be present transiently to promote introduction of sensor 104 into a tissue.
- the introducer may comprise a needle. It is to be recognized that other types of introducers, such as sheaths or blades, may be present in alternative embodiments. More specifically, the needle or similar introducer may transiently reside in proximity to sensor 104 prior to insertion and then be withdrawn afterward. While present, the needle or other introducer may facilitate insertion of sensor 104 into a tissue by opening an access pathway for sensor 104 to follow. For example, the needle may facilitate penetration of the epidermis as an access pathway to the dermis to allow implantation of sensor 104 to take place, according to one or more embodiments.
- the needle or other introducer may be withdrawn so that it does not represent a sharps hazard.
- the needle may be solid or hollow, beveled or non-beveled, and/or circular or non-circular in cross-section.
- the needle may be comparable in cross- sectional diameter and/or tip design to an acupuncture needle, which may have a cross-sectional diameter of about 250 microns. It is to be recognized, however, that suitable needles may have a larger or smaller cross-sectional diameter if needed for particular applications.
- a tip of the needle may be angled over the terminus of sensor 104, such that the needle penetrates a tissue first and opens an access pathway for sensor 104.
- sensor 104 may reside within a lumen or groove of the needle, with the needle similarly opening an access pathway for sensor 104. In either case, the needle is subsequently withdrawn after facilitating insertion.
- Sensor 104 may employ a two-electrode or a three- electrode detection motif, according to various embodiments of the present disclosure.
- Three-electrode motifs may comprise a working electrode, a counter electrode, and a reference electrode.
- Two-electrode motifs may comprise a working electrode and a second electrode, in which the second electrode functions as both a counter electrode and a reference electrode (/.e., a counter/reference electrode).
- the sensing region or sensing layer of sensor 104 may be in contact with the working electrode.
- the various electrodes may be at least partially stacked upon one another, as described in further detail hereinafter. In alternative embodiments, the various electrodes may be spaced apart from one another upon the insertion tail of sensor 104.
- FIG. 2A shows a diagram of an illustrative two-electrode sensor configuration compatible for use in the disclosure herein.
- sensor 200 comprises substrate 212 disposed between working electrode 214 and counter/reference electrode 216.
- working electrode 214 and counter/ reference electrode 216 may be located upon the same side of substrate 212 with a dielectric material interposed in between.
- Sensing region 218 is disposed as at least one layer upon at least a portion of working electrode 214.
- sensing region 218 may comprise multiple spots or a single spot configured for detection of an analyte of interest, such as lactate.
- Membrane 220 overcoats at least sensing region 218 and may optionally overcoat some or all of working electrode 214 and/or counter/ reference electrode 216, in some embodiments.
- One or both faces of sensor 200 may be overcoated with membrane 220.
- membrane 220 may also cover the entirety of sensor 200, including substrate 212.
- Membrane 220 may comprise a polymer having capabilities of limiting analyte flux to sensing region 218, specifically the lactate flux in the disclosure herein.
- Sensor 200 may be operable for assaying lactate by any of coulometric, amperometric, voltammetric, or potentiometric electrochemical detection techniques.
- Three-electrode sensor configurations may be similar to that shown for sensor 200, except for the inclusion of an additional electrode (FIGS. 2B and 2C).
- additional electrode 217 counter/reference electrode 216 may then function as either a counter electrode or a reference electrode, and additional electrode 217 (FIGS. 2B and 2C) fulfills the other electrode function not otherwise fulfilled.
- Working electrode 214 continues to fulfill this function.
- the additional electrode 217 may be disposed upon either working electrode 214 or counter/reference electrode 216, with a separating layer of dielectric material in between. For example, as depicted in FIG. 2B dielectric layers 219a, 219b and 219c separate electrodes 214, 216 and 217 from one another.
- electrodes 214, 216 and 217 may be located upon opposite faces of substrate 212 (FIG. 2C).
- electrode 214 (working electrode) and electrode 216 (counter electrode) may be located upon opposite faces of substrate 212, with electrode 217 (reference electrode) being located upon one of electrodes 214 or 216 and spaced apart therefrom with a dielectric material.
- sensing region 218 may comprise multiple spots or a single spot configured for detection of an analyte of interest, such as lactate.
- Additional electrode 217 may be overcoated with membrane 220 in some embodiments.
- FIGS. 2B and 2C have depicted all of electrodes 214, 216 and 217 as being overcoated with membrane 220, it is to be recognized that only working electrode 214 may be overcoated in some embodiments.
- the thickness of membrane 220 at each of electrodes 214, 216 and 217 may be the same or different. As such, the configuration shown in FIGS. 2B and 2C should be understood as being non-limiting of the embodiments disclosed herein. As in two-electrode configurations, one or both faces of sensor 200 may be overcoated with membrane 220.
- sensing region 218 may comprise a lactate-responsive enzyme. More particularly, the lactate-responsive enzyme may comprise lactate dehydrogenase or lactate oxidase, according to various embodiments. In some embodiments, sensing region 218 may further comprise a stabilizer for lactate dehydrogenase or lactate oxidase, such as catalase. According to still more specific embodiments, the lactate-responsive enzyme, such as lactate dehydrogenase or lactate oxidase, may be covalently bonded to a polymer comprising sensing region or sensing layer 218. Covalent bonding immobilizes the lactate- responsive enzyme upon working electrode 214.
- sensing region or sensing layer 218 may comprise a polymer that is covalently bonded to the lactate-responsive enzyme, such as lactate dehydrogenase or lactate oxidase, and a low-potential osmium complex electron transfer mediator, as disclosed in, for example, U.S. Pat. 6,134,461, which is incorporated herein by reference in its entirety.
- the electron transfer mediator may facilitate conveyance of electrons from lactate to working electrode 214 during a redox reaction. Changes in the signal intensity (e.g., current) at working electrode 214 may be proportional to the lactate concentration and/or the activity of the lactate-responsive enzyme.
- Suitable electron transfer mediators include electroreducible and electrooxidizable ions, complexes or molecules having redox potentials that are a few hundred millivolts above or below the redox potential of the standard calomel electrode (SCE).
- SCE standard calomel electrode
- Other suitable electron transfer mediators may comprise metal compounds or complexes of ruthenium, iron (e.g., polyvinylferrocene), or cobalt, for example.
- Suitable ligands for the metal complexes may include, for example, bidentate or higher denticity ligands such as, for example, a bipyridine, biimidazole, pheanthroline, or pyridyl(imidazole).
- bidentate ligands may include, for example, amino acids, oxalic acid, acetylacetone, diaminoalkanes, or o-diaminoarenes. Any combination of monodentate, bidentate, tridentate, tetradentate, or higher denticity ligands may be present in the metal complex to achieve a full coordination sphere.
- Suitable polymers for inclusion in sensing region 218 include, but are not limited to, polyvinylpyridines (e.g., poly(4- vinylpyridine)), polyimidazoles (e.g., poly(l-vinylimidazole), or any copolymer thereof.
- Illustrative copolymers that may be suitable include, for example, copolymers containing monomer units such as styrene, acrylamide, methacrylamide, or acrylonitrile.
- Covalent bonding of the lactate-responsive enzyme to a polymer or other matrix (e.g., sol-gel) in sensing region 218 may take place via a crosslinker introduced with a suitable crosslinking agent.
- suitable crosslinking agents for reaction with free amino groups in the enzyme may include crosslinking agents such as, for example, polyethylene glycol diglycidylether (PEGDGE) or other polyepoxides, cyanuric chloride, N-hydroxysuccinimide, imidoesters, epichlorohydrin, or derivatized variants thereof.
- Suitable crosslinking agents for reaction with free carboxylic acid groups in the enzyme may include, for example, carbodiimides.
- the lactate-responsive enzyme and/or the electron transfer mediator may be covalently bonded to a polymer or other suitable matrix in sensing region 218, other association means may be suitable as well.
- the lactate-responsive enzyme and/or the electron transfer mediator may be ionically or coordinatively associated with the polymer or other matrix.
- a charged polymer may be ionically associated with an oppositely charged lactate-responsive enzyme or electron transfer mediator.
- the lactate-responsive enzyme and/or the electron transfer mediator may be physically entrained within the polymer or other matrix of sensing region 218.
- one or more components of sensing region 218 may be solvated, dispersed, or suspended in a fluid, instead of being disposed in a solid composition.
- the fluid may be provided with sensor 200 or may be absorbed by sensor 200 from the biological fluid that is undergoing analysis.
- the components which are solvated, dispersed, or suspended in this type of sensing region 218 are non-leachable from sensing region 218.
- non-leachability may be accomplished, for example, by providing barriers (e.g., membranes and/or films) around sensing region 218.
- a barrier is a microporous membrane or film, which allows diffusion of lactate into sensing region 218, but reduces or eliminates diffusion of sensing region 218 components (e.g., an electron transfer agent, an enzyme and/or a reactant) out of sensing region 218.
- sensing region 218 components e.g., an electron transfer agent, an enzyme and/or a reactant
- Such barriers may, in some embodiments, be considered as flux-limiting membranes and may avoid saturating sensor 200 when excessive lactate is present. Flux-limiting membranes of this type may also be used when sensing region contains primarily solid components, as referenced above.
- Sensor 200 may also be configured to analyze for other analytes as well.
- sensor 200 may be further adapted for detecting glucose in vivo by also incorporating suitable sensing functionality for this analyte.
- analyte monitoring system 100 and sensor 200 may comprise additional features and/or functionality that are not necessarily described herein in the interest of brevity.
- the foregoing description of analyte monitoring system 100 and sensor 200 should be considered illustrative and non-limiting in nature.
- methods of the present disclosure may comprise: assaying a biological fluid in vivo with a lactate-responsive sensor adapted for measuring lactate in the biological fluid over a period of time; communicating a signal from the lactate-responsive sensor to a processor; determining a plurality of lactate concentrations with the processor using the signal communicated from the lactate-responsive sensor; correlating, with the processor, a lactate concentration spike, a lactate concentration change, a lactate concentration rate of change, or any combination thereof to an emotional stress event occurring within the period of time; and communicating a notification from the processor to an output medium that an emotional stress event has occurred. Additional method details are provided hereinbelow.
- the sensing systems of the present disclosure may be adapted to determine whether elevated or changing lactate concentrations may be correlated with an emotional stress event. More specifically, the processor in communication with the lactate- responsive sensor may be adapted to correlate a lactate concentration spike, a lactate concentration change, a lactate concentration rate of change, or any combination thereof to an emotional stress event occurring within a given period of time. That is, the processor may analyze and identify lactate concentrations above a specified threshold value, a change in lactate concentrations (regardless of the absolute magnitude of the lactate concentrations themselves), or the rate at which the lactate concentrations are changing.
- Analysis of the rate of change may be especially useful to help identify potential emotional stress events as they occur by identifying concentration trends indicating that a specified lactate concentration threshold may be exceeded. Doing so may facilitate a more rapid response to an emotional stress event.
- the specified threshold may be determined based upon retrospective analysis of a given user's baseline lactate levels or those typically produced in an emotional stress event.
- a threshold lactate level such as about 1.5 mM or above, may be specified.
- Other suitable threshold lactate levels may include about 0.5 mM or above, or about 1 mM or above, or about 1.25 mM or above, or about 1.75 mM or above, or about 2.5 mM or above, for example.
- the chosen threshold level may depend, at least in part, upon the type of emotional stress that one intends to identify as well as to accommodate lactate concentration variability in different individuals. If one or more of the foregoing conditions are met, the processor may perform an additional query to determine if the elevated lactate levels can be correlated to a benign factor leading to elevated lactate levels, such as eating or exercising. Otherwise, the elevated lactate levels may be identified as being associated with an emotional stress event or potential emotional stress event. Once a potential emotional stress event has been identified, the sensing systems may perform additional actions or be adapted to perform additional actions, as described further hereinbelow.
- the processor associated with the sensing systems is further adapted to correlate a measured lactate concentration, concentration change, and/or rate of concentration change with potential emotional stress-related events.
- the sensing systems may be adapted to identify other lactate-altering factors and/or determine if the elevated or changing lactate concentrations are unlikely to be associated with an emotional stress event. More specifically, the sensing systems may be adapted to determine whether other lactate-altering factors have occurred and if they occurred at the same time as the lactate spike, concentration change, or concentration rate of change.
- the sensing systems of the present disclosure may further comprise a clock, an actigraph (e.g., to track sleep times or sleep patterns), an exercise monitor (e.g., incorporating a pedometer, altimeter, temperature monitor, heart rate monitor, position monitor, accelerometer, or the like), or any combination thereof communicatively coupled to the processor.
- the processor is further adapted to determine, based upon a reading from the clock, the actigraph, the exercise monitor, or any combination thereof, that the lactate concentration spike, the lactate concentration change, the lactate concentration rate of change, or any combination thereof is not associated with an emotional stress event occurring within the period of time. Further details are provided below regarding how the processor utilizes data provided by a clock (time), actigraph (sleep patterns), and/or an exercise monitor (e.g., heart rate, position, acceleration or the like) to determine whether an emotional stress event has occurred.
- the sensing systems of the present disclosure may comprise a clock and an exercise monitor communicatively coupled to the processor, and optionally an actigraph.
- the processor is further adapted to determine, based upon a reading from the clock or actigraph and a reading from the exercise monitor that the lactate concentration spike, the lactate concentration change, the lactate concentration rate of change, or any combination thereof is not associated with an emotional stress event occurring within the period of time.
- the sensing systems disclosed herein may further comprise a user input interface communicatively coupled to the processor.
- the user input interface is adapted such that a wearer (/.e., a primary user) may enter times associated with one or more of exercising, eating or sleeping.
- the sensing systems may further accept user input to aid in determining whether a lactate concentration spike, concentration change, and/or concentration rate of change is associated with an emotional stress event.
- the user inputs may override a time, sleep determination and/or exercise reading conveyed to the processor from a clock or exercise monitor.
- a non-wearer such as a parent, caregiver or other concerned individual, may additionally provide user input as well (e.g., if the primary user is unable to provide input or requires supervision).
- the user inputs may also be entered using a remote device or remote terminal, particularly when the individual providing the user inputs is not the primary user.
- the processor may be configured to determine if a lactate spike, concentration change, and/or concentration rate of change occurred at a time when a wearer (/.e., a primary user) of the sensor was likely to be sleeping. Since sleep is a time of relaxation and a wearer of the sensor is unlikely to experience a detrimental emotional stress event during sleep, the sensing system may be adapted to not report irregular or elevated lactate levels that occur when the wearer is sleeping. The lactate measurements obtained during sleep may still be recorded and/or archived, however.
- the sensing systems may comprise a clock communicatively coupled to the processor, wherein the processor is configured to read the time specified by the clock and determine if the wearer is likely to be sleeping.
- the time identified by the processor as being designated or specified for sleep may be adjusted based upon individualized sleep schedules and other factors (e.g., input by a primary user or other individual), or may be automatic based on actimetry measurements that track movement of the wearer during sleep. In alternative embodiments, an actimeter may be read directly to determine if a wearer is sleeping when elevated or irregular lactate levels occur.
- the sensing systems may further query a wearer in response to irregular or elevated lactate levels that occur during a time designated or specified for sleeping. For example, the sensing systems may query whether the wearer was awake during the designated or specified sleep time, experienced a nightmare while sleeping, or watched a scary late night movie. Actimetry measurements may also be used alone or in combination with a clock to determine if the user was sleeping during a time when elevated or irregular lactate levels occurred. Upon confirming that a lactate spike, concentration change, or concentration rate of change occurred during sleep or due to a nightmare, the sensing systems may determine that a potentially harmful emotional stress event did not occur.
- the sensing systems may determine that an emotional stress event occurred. Thus, in certain instances, user input may override the designated sleep time to aid in identifying an emotional stress event. Should the sensing systems determine that the wearer is indeed awake (e.g., automatically using an actimetry reading), the sensing systems may query or prompt the wearer about their emotional state or suggest a suitable calming intervention. If the sensing systems cannot conclusively determine that the wearer is awake, no query or prompt is immediately made, so as to avoid unnecessarily waking the wearer.
- the processor of the sensing systems may be adapted to determine if a lactate spike, concentration change, and/or concentration rate of change occurred at a time when a wearer of the sensor was exercising.
- An exercise monitor may be communicatively coupled with the processor in order to determine whether a wearer of the sensor was exercising when a lactate spike, concentration change, and/or concentration rate of change occurred.
- the exercise monitor like the clock or the actigraph, may be integral to the lactate-responsive sensors or sensing systems of the present disclosure or provided as a separate component in electronic communication with the sensing systems.
- the sensing systems may query data received from the exercise monitor and determine if a marker of exercise occurred during the time a lactate spike, concentration change, and/or concentration rate of change occurred.
- Markers of exercise may include, for example, an elevated heart rate, a lowered blood oxygen content, a change in position (e.g., a change in altitude, latitude/longitude, and/or step count increase, or the like), a change in acceleration, or any combination thereof.
- the exercise monitor may be a designated fitness device, such as a Fitbit, Garmin, or a simple pulse monitoring device.
- the processor may be in communication with a smartphone or smartwatch application designated for monitoring a user's fitness level.
- the exercise monitor may contain an internal clock, such that the exercise monitor can communicate the time exercise occurred to the processor.
- a clock distinct from the exercise monitor may be synched with the exercise monitor and used to determine whether exercise was occurring during a designated time.
- the clock used for determining the time when exercise occurred may be the same clock as that used to determine whether a wearer of the sensor is likely to be sleeping.
- the exercise monitor may include a separate clock as a component thereof.
- Exercise monitors that may be communicatively coupled to the processor are not believed to be particularly limited.
- Illustrative exercise monitors that may be suitably in communication with the processor include, but are not limited to, a heart rate monitor, a position monitor (e.g., a GPS device or altimeter), an accelerometer, a pedometer, or any combination thereof.
- the sensing systems may further query a wearer whether they indeed exercised during a specified period of time. For example, the sensing system may query the wearer in response to a lactate concentration spike, concentration change, and/or concentration rate of change. An exercise query may also occur if a wearer is not wearing an exercise monitor at all or data from the exercise monitor is not properly communicated to the processor. In other embodiments, an exercise query may occur when the processor is unable to determine upon reading data from the exercise monitor whether an exercise event occurred.
- the sensing systems may designate a lactate concentration spike, concentration change, and/or concentration rate of change as not being related to an emotional stress event.
- the sensing systems may query a wearer whether data recorded by the exercise monitor was indeed due to an exercise event. For example, an elevated heart rate measured by a pulse monitor might be incorrectly designated as an exercise event when, in fact, the elevated heart rate was due to an emotional stress event, such as an argument.
- the sensing systems may override the identification of an exercise event and correlate the observed lactate concentration spike, concentration change, and/or concentration rate of change with an emotional stress event. The user of the sensing systems or another individual may override such identification.
- the processor may query multiple types of exercise data received from the exercise monitor to determine whether an exercise event occurred. For example, an elevated heart rate occurring without an associated change in position, acceleration or elevation may not be designated as an exercise event, according to some embodiments. As such, if the exercise data is inconsistent, the processor may further query a wearer to determine whether an exercise event indeed occurred and/or designate an associated lactate concentration spike, concentration change, and/or concentration rate of change as being due to an emotional stress event.
- methods of the present disclosure may further comprise: communicating one or more variables to the processor within the period of time, and determining with the processor based upon the one or more variables whether the lactate concentration spike, the lactate concentration change, and/or the lactate concentration rate of change is associated with an emotional stress event.
- the one or more variables may include, for example, time of day, acceleration, position, altitude, heart rate, step count, an actimetry reading, or any combination thereof.
- the lactate concentration spike, the lactate concentration change, and/or the lactate concentration rate of change is not communicated to the output medium as an emotional stress event.
- user input may override the designation of a time of day specified for sleeping.
- methods of the present disclosure may comprise determining with the processor whether a user of the lactate-responsive sensor has been sleeping, and if the processor determines the user has been sleeping (either from user input or from time of day analysis or actimeter data), the lactate concentration spike, the lactate concentration change, and/or the lactate concentration rate of change is not communicated to the output medium as an emotional stress event, although the lactate measurement may still be stored in a memory of the sensing systems for a period of time, however.
- the lactate concentration spike, the lactate concentration change, and/or the lactate concentration rate of change is not communicated to the output medium as an emotional stress event.
- user input may override the designation of an exercise event at a given time.
- methods of the present disclosure may comprise determining with the processor whether a user of the lactate-responsive sensor has been exercising, and if the processor determines the user has been exercising (either from user input or analysis of data from an exercise monitor), the lactate concentration spike, the lactate concentration change, and/or the lactate concentration rate of change is not communicated to the output medium as an emotional stress event, although the lactate measurement may still be stored in a memory of the sensing systems for a period of time, however.
- FIG. 3 shows an illustrative decision tree that may be executed by the processor within the sensing systems of the present disclosure, in which elevated lactate levels occurring during sleep or exercise may be determined as being unrelated to an emotional stress event. It is to be recognized that the decision order shown in FIG. 3 need not necessarily occur in the order depicted. [0055] As shown in decision tree 300, elevated or irregular lactate concentrations may be detected in operation 310. If the lactate spike, change in lactate concentration, and/or rate of change in lactate concentration does not exceed one or more threshold values, emotional stress is not determined in operation 320.
- decision tree 300 next evaluates in operation 330 whether a clock indicates a time designated for sleeping or an actimeter indicates that a user is possibly sleeping based on the user's level of activity or movement.
- the term "designated sleep time” encompasses any of an automated determination of sleep through actimetry and/or from time of day analysis with a clock. If the clock or an actimeter indicates a designated sleep time, decision tree 300 may optionally query in operation 340 whether a user was indeed sleeping. If so, operation 350 may determine that an emotional stress event has not occurred. Otherwise, decision tree 300 may continue evaluating in operation 360 whether other factors may be affecting the lactate concentration. Namely, operation 360 may determine whether a user has been exercising.
- operation 360 determines that a user has been exercising
- operation 370 determines that an emotional stress event has not occurred. If no exercise is detected by operation 360 in decision tree 300, operation 380 may then determine that an emotional stress event has occurred. An alert or user prompt may be suggested in operation 390, according to some embodiments.
- Lactate concentrations may also fluctuate as a consequence of eating.
- the sensing systems of the present disclosure may further query a user whether they ate during or prior to the time when a lactate spike, change in lactate concentration, and/or rate of change in lactate concentration occurred.
- the user may enter a time when they ate, or the user may respond to a query from the processor whether they ate at a specified time (/.e., a time during or before that at which a lactate spike, change in lactate concentration, and/or rate of change in lactate concentration was observed).
- methods of the present disclosure may further comprise: determining with the processor whether a user (wearer) of the lactate-responsive sensor has been eating. Determining may comprise the user (wearer) responding to one or more queries from the processor to evaluate whether eating occurred at a specified time. In addition to the wearer of the lactate-responsive sensor, other individuals may respond to an eating query according to various embodiments.
- the sensing systems may evaluate blood glucose levels in vivo in order to evaluate whether a user has recently eaten. If blood glucose levels are rising, for example, the sensing systems may infer that a user has recently consumed food. Sensing of this type may be overridden if the user experiences irregular blood glucose levels, such as in diabetic individuals.
- a sensor separate from the lactate-responsive sensor may be used for evaluating blood glucose levels in vivo, with information from the separate sensor being communicated to the sensing systems. If the processor determines the user has been eating, the lactate spike, change in lactate concentration, and/or rate of change in lactate concentration is not communicated to the output medium as an emotional stress event.
- the sensing systems of the present disclosure may further comprise a glucose- responsive sensor, according to various embodiments.
- the glucose- responsive sensor may comprise a processor that is communicatively coupled with the processor associated with the lactate-responsive sensor.
- the processor associated with the lactate- responsive sensor may be further adapted to determine glucose concentrations measured by the glucose-responsive sensor
- methods of the present disclosure may comprise: determining with the processor whether a user (wearer) of the lactate-responsive sensor has been sleeping, exercising, eating, or any combination thereof. If the processor determines the user (wearer) has been sleeping, exercising, eating, or any combination thereof, the lactate spike, the change in lactate concentration, and/or the rate of change in lactate concentration is not communicated to the output medium as an emotional stress event.
- FIG. 4 shows an illustrative decision tree that may be executed by the processor within the sensing systems of the present disclosure, in which elevated lactate levels occurring during sleep or exercise or as a result of eating may be determined as being unrelated to an emotional stress event. It is likewise to be recognized that the decision order shown in FIG. 4 need not necessarily occur in the order depicted.
- Decision tree 400 of FIG. 4 is similar in several aspects to decision tree 300 of FIG. 3. Namely, operations 400, 410, 420, 430, 440, 450, 460, and 470 in decision tree 400 substantially correspond to operations 300, 310, 320, 330, 340, 350, 360, and 370 in decision tree 300 and are not described again in the interest of brevity.
- operation 480 may then query or determine (e.g., by evaluating blood glucose concentrations) whether a user ate recently or at a specified time. If the user ate during a specified time period, operation 490 may determine that an emotional stress event has not occurred. In contrast, if operation 480 determines that eating did not occur, operation 495 may then communicate to an output medium that an emotional stress event may have occurred. An alert or user prompt may be suggested in operation 500, according to some embodiments.
- the sensing systems and methods of the present disclosure may be further adapted to interface or interact with a user (wearer) to notify and/or intervene with the user in the case an emotional stress event being detected (e.g. , operations 390 and 500 in FIGS. 3 and 4).
- the sensing systems and methods may suggest further action on the part of a user in the event of emotional stress being detected. Interfacing and/or interacting with a user may take place in any of a variety of forms or actions.
- the sensing systems and methods may query a user concerning their emotional state (e.g., "Are you okay?") ⁇
- the sensing systems and methods may suggest performing a relaxation technique, taking medication, or the like.
- the sensing systems and methods may convey an audible, visual, or other sensory-stimulating alarm (e.g., a haptic or mild electric shock) to a user should an emotional stress event be detected.
- the methods of the present disclosure may further comprise prompting a user of the lactate-responsive sensor for a response after communicating a notification of an emotional stress event.
- methods of the present disclosure may further comprise receiving one or more user inputs with the processors, and determining with the processor, based upon the one or more user inputs, whether the lactate concentration spike, the lactate concentration change, and/or the lactate concentration rate of change is associated with an emotional stress event.
- the one or more user inputs may comprise a range of times associated with one or more of exercising, eating, sleeping, or any combination thereof.
- the one or more user inputs may comprise a response to a query from the sensing systems, such as the user's emotional state or whether the user has taken action to relieve emotional stress.
- the sensing systems and methods may relay a notification to another person designated by the user (wearer), who may intervene on the user's behalf.
- the notification to the other person may occur in addition to a notification provided to the user, or as an alternative to a notification provided to a user.
- the sensing systems and methods may be adapted to relay a notification to a user's spouse, parent, child, teacher, friend, doctor, therapist, or other individual who may interface with the user and potentially help them in relieving their emotional stress, particularly if the user is unable to perform such actions on their own.
- Embodiments disclosed herein include:
- the sensing systems comprise: a lactate-responsive sensor adapted for detecting lactate in vivo ; and a processor communicatively coupled to the lactate-responsive sensor; wherein the processor is adapted to determine a plurality of lactate concentrations measured by the lactate-responsive sensor over a period of time, and wherein the processor is further adapted to correlate a lactate concentration spike, a lactate concentration change, a lactate concentration rate of change, or any combination thereof to an emotional stress event occurring within the period of time.
- B Methods for monitoring emotional stress.
- the methods comprise: assaying a biological fluid in vivo with a lactate- responsive sensor adapted for measuring lactate in the biological fluid over a period of time; communicating a signal from the lactate-responsive sensor to a processor; determining a plurality of lactate concentrations with the processor using the signal communicated from the lactate-responsive sensor; correlating, with the processor, a lactate concentration spike, a lactate concentration change, a lactate concentration rate of change, or any combination thereof to an emotional stress event occurring within the period of time; and communicating a notification from the processor to an output medium that an emotional stress event has occurred.
- Element 1 wherein a housing for the lactate-responsive sensor is adapted to be worn on-body, and at least a portion of the lactate-responsive sensor protrudes from the housing for insertion in vivo.
- Element 2 wherein the lactate-responsive sensor comprises a working electrode having a sensing layer comprising a lactate-responsive enzyme disposed thereupon.
- Element 3 wherein the lactate-responsive enzyme is covalently bonded to a polymer comprising the sensing layer.
- Element 4 wherein the sensing layer further comprises catalase as a stabilizer for the lactate-responsive enzyme.
- Element 5 wherein the lactate-responsive enzyme is lactate dehydrogenase or lactate oxidase.
- Element 6 wherein the sensing system further comprises: a clock, an actimeter, an exercise monitor, or any combination thereof communicatively coupled to the processor; wherein the processor is further adapted to determine, based upon a reading from the clock, the actimeter, the exercise monitor, or any combination thereof, that the lactate concentration spike, the lactate concentration change, the lactate concentration rate of change, or any combination thereof is not associated with an emotional stress event occurring within the period of time.
- Element 7 wherein the sensing system further comprises: a clock and an exercise monitor communicatively coupled to the processor; wherein the processor is further adapted to determine, based upon a reading from the clock and a reading from the exercise monitor, that the lactate concentration spike, the lactate concentration change, the lactate concentration rate of change, or any combination thereof is not associated with an emotional stress event occurring within the period of time.
- Element 8 wherein the sensing system further comprises: a user input interface communicatively coupled with the processor; wherein the user input interface is adapted for entering times associated with one or more of exercising, eating or sleeping.
- Element 9 wherein the method further comprises: communicating one or more variables to the processor within the period of time, the one or more variables being selected from the group consisting of time of day, an actimetry reading, acceleration, position, altitude, heart rate, and any combination thereof; and determining with the processor based upon the one or more variables whether the lactate concentration spike, the lactate concentration change, the lactate concentration rate of change, or any combination thereof is associated with an emotional stress event.
- Element 10 wherein, if the one or more variables are measured at a time of day specified for sleeping, the lactate concentration spike, the lactate concentration change, the lactate concentration rate of change, or any combination thereof is not communicated to the output medium as an emotional stress event.
- Element 11 wherein, if the one or more variables are determined by the processor to be suggestive of exercise, the lactate concentration spike, the lactate concentration change, the lactate concentration rate of change, or any combination thereof is not communicated to the output medium as an emotional stress event.
- Element 12 wherein the method further comprises: determining with the processor whether a user of the lactate-responsive sensor has been sleeping; wherein, if the processor determines the user has been sleeping, the lactate concentration spike, the lactate concentration change, the lactate concentration rate of change, or any combination thereof is not communicated to the output medium as an emotional stress event.
- Element 13 wherein the method further comprises: determining with the processor whether a user of the lactate-responsive sensor has been exercising; wherein, if the processor determines the user has been exercising, the lactate concentration spike, the lactate concentration change, the lactate concentration rate of change, or any combination thereof is not communicated to the output medium as an emotional stress event.
- Element 14 wherein the method further comprises: determining with the processor whether a user of the lactate-responsive sensor has been eating; wherein, if the processor determines the user has been eating, the lactate concentration spike, the lactate concentration change, the lactate concentration rate of change, or any combination thereof is not communicated to the output medium as an emotional stress event.
- Element 15 wherein the method further comprises: determining with the processor whether a user of the lactate-responsive sensor has been sleeping, exercising, eating, or any combination thereof; wherein, if the processor determines the user has been sleeping, exercising, eating, or any combination thereof, the lactate concentration spike, the lactate concentration change, the lactate concentration rate of change, or any combination thereof is not communicated to the output medium as an emotional stress event.
- Element 16 wherein the method further comprises: prompting a user of the lactate-responsive sensor for a response after communicating the notification of the emotional stress event to the output medium.
- Element 17 wherein the method further comprises: receiving one or more user inputs with the processor, the one or more user inputs comprising a range of times associated with one or more of exercising, eating, sleeping or any combination thereof; and determining with the processor based upon the one or more user inputs whether the lactate concentration spike, the lactate concentration change, the lactate concentration rate of change, or any combination thereof is associated with an emotional stress event.
- exemplary combinations applicable to A and B include:
- the sensing system of A in combination with elements 1 and 2; 1 and 3; 1, 3 and 4; 1 and 5; 1, 2 and 3; 1-4; 1, 2 and 5; 2 and 3; 2-4; 2 and 5; 2-5; 1 and 6; 2 and 6; 3 and 6; 5 and 6; 1 and 7; 2 and 7; 3 and 7; 5 and 7; 1 and 8; 2 and 8; 3 and 8; 4 and 8; 6 and 8; and 7 and 8.
- a FREESTYLE LIBRETM (Abbott Diabetes Care) sensor housing was fitted with a lactate-responsive sensor, and lactate levels were monitored continuously in vivo for several days. The time was recorded at which each lactate concentration measurement was made. Concurrently, the time of day and physical activity were monitored using a clock and an exercise monitoring device, respectively. A plot of in vivo measured lactate concentrations as a function of time is shown in FIG. 5. Lactate concentrations above 1.5 mM were further analyzed as potentially being related to an emotional stress event.
- lactate spikes 3 and 5 were determined as being unrelated to emotional stress, since they occurred during confirmed non-waking hours.
- lactate spikes 2 and 6 occurred in conjunction with exercise and were similarly determined to be unrelated to an emotional stress event.
- Lactate spikes 1 and 4 in contrast, occurred during waking hours and did not occur in conjunction with exercise. Provided that lactate spikes 1 and 4 do not occur as a result of eating, they may be correlated to an emotional stress event. Some individuals do not exhibit a lactate spike in conjunction with eating, whereas others do. As lactate spikes 1 and 4 occur, a wearer of the lactate-responsive sensor may be prompted to take further action.
- the phrase "at least one of” preceding a series of items, with the terms “and” or “or” to separate any of the items, modifies the list as a whole, rather than each member of the list (i.e., each item).
- the phrase "at least one of” allows a meaning that includes at least one of any one of the items, and/or at least one of any combination of the items, and/or at least one of each of the items.
- the phrases “at least one of A, B, and C” or “at least one of A, B, or C” each refer to only A, only B, or only C; any combination of A, B, and C; and/or at least one of each of A, B, and C.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862668347P | 2018-05-08 | 2018-05-08 | |
PCT/US2019/020931 WO2019216977A1 (en) | 2018-05-08 | 2019-03-06 | Sensing systems and methods for identifying emotional stress events |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3790465A1 true EP3790465A1 (en) | 2021-03-17 |
Family
ID=66049695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19716019.5A Pending EP3790465A1 (en) | 2018-05-08 | 2019-03-06 | Sensing systems and methods for identifying emotional stress events |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3790465A1 (en) |
WO (1) | WO2019216977A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6134461A (en) | 1998-03-04 | 2000-10-17 | E. Heller & Company | Electrochemical analyte |
US9949672B2 (en) * | 2009-12-17 | 2018-04-24 | Ascensia Diabetes Care Holdings Ag | Apparatus, systems and methods for determining and displaying pre-event and post-event analyte concentration levels |
US11346798B2 (en) * | 2010-07-12 | 2022-05-31 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and device for tuning multiplexed markers for disease assay |
WO2014063160A1 (en) * | 2012-10-19 | 2014-04-24 | Basis Science, Inc. | Detection of emotional states |
US20150277572A1 (en) * | 2012-10-24 | 2015-10-01 | Intel Corporation | Smart contextual display for a wearable device |
AU2016280696B2 (en) * | 2015-06-15 | 2021-11-18 | Abbott Diabetes Care Inc. | Stabilized lactate responsive enzymes, electrodes and sensors, and methods for making and using the same |
-
2019
- 2019-03-06 EP EP19716019.5A patent/EP3790465A1/en active Pending
- 2019-03-06 WO PCT/US2019/020931 patent/WO2019216977A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2019216977A1 (en) | 2019-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11879887B2 (en) | End of life detection for analyte sensors | |
US20220386903A1 (en) | Systems, devices, and methods related to the individualized calibration and/or manufacturing of medical devices | |
CN111818849A (en) | Annotation and event log information associated with an analyte sensor | |
US20140024907A1 (en) | Method and system to indicate hyperglycemia or hypoglycemia for people with diabetes | |
US9592002B2 (en) | Method and system to derive multiple glycemic patterns from glucose measurements during time of the day | |
KR20140008317A (en) | Analyte testing method and system with high and low analyte trends notification | |
Signal et al. | Impact of retrospective calibration algorithms on hypoglycemia detection in newborn infants using continuous glucose monitoring | |
AU2020216330B2 (en) | Analyte sensors and sensing methods for dual detection of glucose and ethanol | |
US20210228128A1 (en) | Sensing systems and methods for identifying emotional stress events | |
AU2019325918B2 (en) | Sensors and methods for measuring pH | |
JP2022509742A (en) | Measurement of elevated levels of circulating ketone bodies in physiological fluids | |
Wang et al. | Long-term home study on nocturnal hypoglycemic alarms using a new fully implantable continuous glucose monitoring system in type 1 diabetes | |
KR20150038189A (en) | Method and system to manage diabetes using multiple risk indicators for a person with diabetes | |
US20140275903A1 (en) | System and method for quick-access physiological measurement history | |
EP3790465A1 (en) | Sensing systems and methods for identifying emotional stress events | |
Sly et al. | Blood glucose monitoring devices: current considerations | |
RU2723703C2 (en) | Sensor device for determining at least one analyte in user's physiological environment | |
Henning | Commercially available continuous glucose monitoring systems | |
US9903879B2 (en) | Method to allow for linking temporal record with physiological measurement in buttonless physiological meters |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20201123 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230530 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20231117 |